Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project

Table 2 Feasibility and safety data

	CVVH (n= 35)	CVVHD (n= 38)	P-value
Duration RRT prescribed, hrs	146 ± 240	145 ± 156	0.88
Duration RRT received, hrs	130 ± 222	128 ± 142	0.87
Mean pre-filter replacement solution flow, mL/hr	1533 ± 442	0	n/a
Mean post-filter replacement solution flow, mL/hr	1440 ± 488	180 ± 140	n/a
Mean dialysate flow, mL/hr	0	2871 ± 872	n/a
Mean RRT dose, mL/kg/hr	33.6 ± 7.4	34.7 ± 4.4	0.50
Prescribed dose delivered, %	84.7 ± 16.3	87.8 ± 13.7	0.73
Net ultrafiltration, L/day	1.7 ± 2.2	0.8 ± 4.1	0.98
Days on study therapy	5 (3-7)	4.50 (3.00-10.25)	0.79
Primary reason for CRRT withdrawal			0.75
Death while on CRRT	12 (35%)	10 (27%)
Kidney function recovery	7 (21%)	7 (19%)
Transfer to intermittent hemodialysis	12 (35%)	14 (38%)
Withdrawal of life support	3 (9%)	6 (16%)
Catheter changes/day of therapy	0.09 ± 0.2	0.1 ± 0.2	0.92
Units RBCs transfused/day of therapy	0.3 ± 0.3	0.4 ± 0.7	0.38
Unscheduled circuit changes/day of therapy	0.2 ± 0.3	0.2 ± 0.2	0.36
Study days with receipt of norepinephrine, %	61.8 ± 36.2	65.7 ± 7.5	0.41
Study days with receipt of vasopressin, %	35.4 ± 35.9	43.0 ± 43.6	0.51

Continuous data are displayed as mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables are displayed as n (%); n/a, not applicable. Data are restricted to patients who initiated therapy with the CRRT mode to which they had been allocated. RRT, renal replacement therapy; CRRT, continuous renal replacement therapy; RBCs, red blood cells; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemofiltration.

ISSN: 1364-8535